Publications by authors named "Anna-Maria Jegg"

Claim this Profile
P
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Anna-Maria Jegg

Nat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, Anna-Maria Jegg

J Immunother Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Stefan Bissinger, Carina Hage, Vinona Wagner, Ilona-Petra Maser, Verena Brand, Anna-Maria Jegg

Sci Transl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Philippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, Christophe Le Tourneau, Maud Toulmonde, Anna-Maria Jegg

Eur J Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Jean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, Dmitriy Zamarin, Tara Mitchell, Anna-Maria Jegg

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Michael A Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H Ries

J Immunother Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Philippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, Christophe Le Tourneau, Maud Toulmonde, Anna-Maria Jegg

Lancet Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Anna-Maria Jegg, Toby M Ward, Elizabeth Iorns, Nicholas Hoe, Jinyao Zhou

Breast Cancer Res Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis